Related Experiment Video

Updated: Jun 2, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer

Simon Rieder1, Christoph W Michalski, Helmut Friess

  • 1Department of Surgery, Technische Universität München, Ismaninger Strasse 22, Munich, Germany.

Anti-Cancer Agents in Medicinal Chemistry
|April 16, 2011
PubMed

Insights

Targeting insulin-like growth factor-1 (IGF-1) and its receptor (IGF-1R) shows promise in cancer therapy, particularly pancreatic cancer. Combination therapies with mTOR inhibitors may improve outcomes by counteracting feedback signaling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Insulin-like growth factor-1 (IGF-1) signaling via IGF-1R activates the PI3K/Akt pathway, promoting cell survival and is overexpressed in pancreatic cancer.
  • Mammalian target of rapamycin (mTOR) mediates PI3K/Akt signaling, but its inhibition can paradoxically up-regulate IGF-1R signaling.
  • Targeting IGF-1/IGF-1R presents challenges due to ubiquitous expression and potential off-target effects on the insulin receptor, causing hyperglycemia.

Purpose of the Study:

  • To explore the therapeutic potential of targeting the IGF-1/IGF-1R pathway in cancer.
  • To investigate combination therapies involving IGF-1/IGF-1R inhibitors and mTOR inhibitors for improved anti-cancer effects.
  • To address the challenges and side effects associated with IGF-1R targeted agents.

Main Methods:

  • Review of current research on IGF-1/IGF-1R signaling in cancer.
  • Analysis of ongoing clinical trials (Phase I/II) for IGF-1 and IGF-1R targeted agents.
  • Exploration of theoretical benefits of combining IGF-1/IGF-1R inhibitors with mTOR inhibitors.

Main Results:

  • IGF-1 and IGF-1R are validated targets in various cancers, with ongoing trials investigating their efficacy.
  • Combination therapy of IGF-1R inhibitors with chemotherapy is being studied for pancreatic cancer.
  • Combining mTOR inhibitors with IGF-1/IGF-1R inhibitors may counteract feedback loops and enhance therapeutic outcomes.

Conclusions:

  • IGF-1 and IGF-1R represent promising therapeutic targets for cancer treatment.
  • Combination strategies, particularly with mTOR inhibitors, hold potential for improving clinical outcomes in cancer therapy.
  • Further research and clinical trials are warranted to optimize these targeted approaches.

More Related Videos

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...